ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSK..HRIS..MTNORS..SM..................*JBDM Ver 0.1.63 (23 May 2017) - 2999001/03099298CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120190522W173deBibliographieenBibliographyfrBibliographieEP15704827.3201501292016081720180601enenen20140161720140130GB2019052220192120161207201649201903202019122018100520190522201921A61K 31/435 20060101AFI20150811BHEP A61K 31/4525 20060101ALI20150811BHEP A61K 31/496 20060101ALI20150811BHEP A61K 31/7072 20060101ALI20150811BHEP A61K 38/12 20060101ALI20150811BHEP A61P 31/04 20060101ALI20150811BHEP A61P 31/10 20060101ALI20150811BHEP deZIDOVUDINKOMBINATIONSTHERAPIEN ZUR BEHANDLUNG VON MIKROBIELLEN INFEKTIONENenZIDOVUDINE COMBINATION THERAPIES FOR TREATING MICROBIAL INFECTIONSfrTHÉRAPIES COMBINATOIRES PAR ZIDOVUDINE POUR LE TRAITEMENT D'INFECTIONS MICROBIENNESWO-A1-2007/054599PANTOPOULOU ET AL: "Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, ELSEVIER SCIENCE, AMSTERDAM, NL, vol. 29, no. 1, 22 December 2006 (2006-12-22), pages 51-55, XP005812322, ISSN: 0924-8579, DOI: 10.1016/J.IJANTIMICAG.2006.09.009B R KEITH ET AL: "In vivo efficacy of zidovudine (3'-azido-3'-deoxythymidine) in experimental gram-negative-bacterial infections.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 33, no. 4, April 1989 (1989-04), pages 479-483, XP055179911, ISSN: 0066-4804, DOI: 10.1128/AAC.33.4.479DOLÉANS-JORDHEIM A ET AL: "Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains", EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, SPRINGER, BERLIN, DE, vol. 30, no. 10, 15 April 2011 (2011-04-15), pages 1249-1256, XP019951616, ISSN: 1435-4373, DOI: 10.1007/S10096-011-1220-3 cited in the applicationMASCELLINO M T ET AL: "In vitro activity of zidovudine alone and in combination with ciprofloxacin against Salmonella and Escherichia coli", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, ELSEVIER SCIENCE B.V., AMSTERDAM, NL, vol. 7, no. 1, June 1993 (1993-06), pages 23-28, XP023924467, ISSN: 0928-8244, DOI: 10.1111/J.1574-695X.1993.TB00377.X [retrieved on 1993-06-01]E TAGLIAFERRI ET AL: "Synergistic Activity of Colistin (COL) plus Rifampin (RIF) Against COL-Resistant (R) and Susceptible (S) KPC-producing Klebsiella pneumoniae (KPC-KP) clinical isolates", ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 52, September 2012 (2012-09), page E796, XP055151648,CHITNIS S ET AL: "In vitro synergistic activity of colistin with aminoglycosides, beta-lactams and rifampin against multidrug-resistant gram-negative bacteria", JOURNAL OF CHEMOTHERAPY, SCRIT, IT, vol. 19, no. 2, April 2007 (2007-04), pages 226-229, XP009169446, ISSN: 1120-009XR. K. BHARDWAJ: "Piperine, a Major Constituent of Black Pepper, Inhibits Human P-glycoprotein and CYP3A4", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 302, no. 2, August 2002 (2002-08), pages 645-650, XP055180107, ISSN: 0022-3565, DOI: 10.1124/jpet.102.034728 cited in the applicationCOATES, AnthonyDepartment of Clinical Sciences St George's University of London Cranmer TerraceLondon SW17 0REGBHU, YanminDepartment of Clinical Sciences St George's University of London Cranmer TerraceLondon SW17 0REGBHelperby Therapeutics Limited101551952P104211EP REB66 Lincoln's Inn FieldsLondon WC2A 3LHGBD Young & Co LLP101533551120 HolbornLondon EC1N 2DYGBALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTRGB201505020920150129enWO201511434020150806201531